Trials / Completed
CompletedNCT04834752
Effect of H2 Receptor Antagonist and Proton Pump Inhibitor on the Positivity Rates and Clinical Outcomes of COVID-19
Effect of Histamine 2 Receptor Antagonist (H2RA) and Proton Pump Inhibitor (PPI) on the Positivity Rates and Clinical Outcomes of Coronavirus Disease-19 (COVID-19).
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 400,000 (actual)
- Sponsor
- Seoul National University Hospital · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This retrospective cohort study aims to evaluate the effect of proton pump inhibitor (PPI) or histamine-2 receptor antagonist (H2RA) on the clinical outcomes and positivity rates of Coronavirus Disease-19 (COVID-19).
Detailed description
Previous researches on the association between the use of PPI and H2RA and the treatment and prevention of COVID-19 have reported inconsistent findings. This study aimed to evaluate the effect of H2 receptor antagonists and proton pump inhibitors on the clinical outcomes and positivity rates of COVID-19 using the Korean National Health Insurance (NHI) data. This is a retrospective cohort study using the NHI COVID-19 dataset, which includes health insurance data of individuals who underwent COVID-19 PCR test in South Korea. This study aims to evaluate the effect of the use of PPI and H2RA on the positivity rates and clinical outcomes of COVID-19.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| OTHER | No intervention (Retrospective Cohort Observational) | History of PPI and H2RA prescription of the participants who were tested for COVID-19 will be reviewed. |
Timeline
- Start date
- 2021-05-01
- Primary completion
- 2021-12-31
- Completion
- 2021-12-31
- First posted
- 2021-04-08
- Last updated
- 2024-11-29
Locations
1 site across 1 country: South Korea
Source: ClinicalTrials.gov record NCT04834752. Inclusion in this directory is not an endorsement.